[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602823":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":59,"collaborators":62,"id":65,"slug":23,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":23,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":23,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":91,"whyStopped":23,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment with Ketone Supplement","EXPERIMENTAL","Participants (n=25) will receive three doses of a ketone supplement drink daily for seven days.",[13],"Dietary Supplement: Treatment with Ketone Supplement",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment with Placebo","Participants (n=25) will receive three doses of a placebo drink daily for seven days.",[18],"Dietary Supplement: Treatment with Placebo",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DIETARY_SUPPLEMENT",[9],null,{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":23},"Participants (n=25) will receive three doses of a placebo drink for seven days.",[15],[28],{"name":29,"affiliation":5,"role":30},"Peter Manza, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":23,"email":35},"CONTACT","410-706-2814","peter.manza@som.umaryland.edu",{"name":37,"role":33,"phone":38,"phoneExt":23,"email":39},"Kynah Walston, MA","443-974-7951","Kynah.Walston@som.umaryland.edu",[41],{"facility":42,"status":23,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Caron Pennsylvania Addiction Treatment and Rehab Center","Wernersville","Pennsylvania","19565","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-76.0805,40.33009,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":23,"email":58},"Erin Deneke, PhD","610-743-6242","edeneke@caron.org",{"type":30,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Peter Manza","Assistant Professor",[63],{"name":64,"class":6},"Caron Treatment Centers","100602823",false,"NCT07128524","Ketones for Opioid Craving","Ketone Supplementation for Opioid Craving and Withdrawal","Inclusion Criteria:\n\n* Age 18-75 years\n* Meets currents DSM-5 criteria for OUD and admitted for opioid withdrawal management treatment at Caron Treatment Center\n* Willingness to provide signed, informed consent and commit to completing the procedures in the study\n\nExclusion Criteria:\n\n* Current severe gastrointestinal (GI), liver, or other clinically significant physical disease that may interfere with the intake of the ketone supplement (e.g., sever inflammatory bowel disease, cirrhosis).\n* Currently taking (within the past two weeks) GLP-1 receptor agonist medications, e.g. semaglutide, which can interfere with the absorption of the ketone supplement\n* Currently pregnant or lactating, for people of childbearing potential\n* Judged by the principal investigator. study physician, or their designee to be an unsuitable candidate for the study","ALL","18 Years","75 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The goal of this clinical trial is to learn if ketone supplementation (KS) works to reduce craving for opioids for adults with opioid use disorder (OUD) undergoing in-patient acute withdrawal management. The main questions it aims to answer are:\n\n* Does KS reduce craving for opioids in patients with opioid use disorder?\n* Does KS reduce symptoms of opioid withdrawal such as low mood and pain? Researchers will compare KS to a placebo to see if KS works to reduce craving for opioids and reduce withdrawal symptoms in adults entering in-patient acute withdrawal management for opioid use disorder.\n\nParticipants will:\n\n* Be given KS or a placebo three (3) times daily for seven (7) days\n* Complete mood, pain tolerance, and subjective opioid withdrawal assessments",[82],"Opioid Use Disorder",[84,85,86,87,88,89,90],"opioid use disorder","OUD","ketone","ketone supplement","ketone supplementation","craving","withdrawal","NOT_YET_RECRUITING","2026-06-30",{"date":94,"type":95},"2026-07-02","ACTUAL",{"date":97,"type":76},"2026-07",{"date":99,"type":76},"2027-09",{"name":5,"class":6},1]